

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DKT. NO.

BAYER 9-P1

SERIAL NO.

09/472,232  
09/303,621INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Jacques DUMAS, et al.

FILING DATE


December 22, 1998

GROUP

1624  
1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
AA	3,823,161	07/09/74	Lesser			
AB	5,130,331	07/14/92	Pascual			
AC	4,808,588	02/28/89	King			
AD	3,424,760	01/28/69	Helsley et al.			
AE	3,424,761	01/28/69	Helsley et al.			
AF	3,424,762	01/28/69	Helsley et al.			
AG	4,071,524	01/31/78	Banitt			
AH	4,111,683	09/05/78	Singer			
AI	4,437,878	03/20/78	Acker et al.			
AJ	4,643,849	02/17/87	Hirai et al.			
AK	5,773,459	06/30/98	Tang et al.			
AL	5,508,288	04/16/96	Forbes et al.			
AM	4,062,861	12/13/77	Yukinaga et al.			
AN	4,111,680	09/05/78	Yukinaga et al.			
AO	4,116,671	09/26/78	Yukinaga et al.			
AP	4,212,981	07/15/80	Yukinaga et al.			
AQ	5,162,360	11/10/92	Creswell et al.			
AR	4,514,571	04/30/85	Nakai et al.			
AS	3,754,887	08/28/73	Brantley			
AT	3,646,059	02/29/72	Brantley			
AU	5,696,138	12/9/97	Olesen et al.			
AV	5,780,483	7/14/98	Widdowson et al.			
AW	4,405,644	9/20/83	Kabbe et al.			
AX	4,473,579	9/25/84	Devries et al.			
AY	4,526,997	7/2/85	O'Doherty et al.			
AZ	4,468,380	8/28/84	O'Doherty et al.			
BA	4,623,662	11/18/86	De Vries			
BB	4,985,449	1/15/91	Haga et al.			
BC	5,312,820	5/17/94	Ashton et al.			
BD	4,410,697	10/18/83	Török et al.			
BE	4,001,256	1/4/97	Callahan et al.			
BF	5,399,566	3/21/95	Katano et al.			
BG	5,500,424	3/19/96	Nagamine et al.			
BH	5,597,719	1/28/97	Freed et al.			



*Duplicate*

\* These references were cited on the IDS filed on July 21, 2000.

BI	4,183,854	1/80	Crossley			
BJ	3,828,001	8/74	Broad et al.			
BK	4,740,520	4/88	Hallenbach et al.			
BL	5,319,099	6/7/94	Kamata et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
BM	EP 335156	03/11/89	European				X
BN	EP 459887	05/28/91	European				X
BO	EP 371876	11/28/89	European				X
BP	93/24458	12/9/93	WO			X	
BQ	2,146,707	10/12/95	Canada			X	
BR	96/40673	12/19/96	WO			X	
BS	94/14801	07/07/94	WO			X	
BT	94/25012	11/10/94	WO			X	
BU	1,590,870	06/10/81	England			X	
BV	93/18028	09/16/93	WO			X	
BW	94/18170	08/18/94	WO			X	
BX	DE 3305866 A1	02/19/83	Germany				X
BY	95/02591	01/26/95	WO			X	
BZ	95/13067	05/18/95	WO			X	
CA	95/07922	03/23/95	WO			X	
CB	95/31451	11/23/95	WO			X	
CC	A1 96/40675	12/19/96	WO			X	
CD	JP 53 086033		Japan				
CE	JP 51 063170		Japan				
CF	97/49400	12/31/97	WO				
CG	97/49399	12/31/97	WO				
CH	96/40673	12/19/96	WO				
CI	99/00357	1/7/99	WO				
CJ	97/45400	12/4/97	WO				
CK	96/02112	3/8/90	WO				
CL	99/00370		WO				
CM	97/29743		WO				
CN	98/22432		WO				
CO	96/25157 A1	8/22/96	WO				
CP	97/40028 A1	10/30/97	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CQ	Dumas, J., "CAS Substructure," May 6, 1997, pages 1-29.
----	---

CR	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pages 1-19.
CS	Scott, Bill, "Substructure #2," November 25, 1997, pages 1-3.
CT	"Beilstein number" Collection, 28 pages.
CU	"Beilstein Collection," 4 pages.
CV	Scott, Bill, "Substructure Search," December 2, 1997, pages 1-51.
CX	Substructure Search, pages 1-30.
CY	Derwent World Patents Index Search, pages 20-26.
CZ	Abstract of EP 116,932
DA	Abstract of EP 676,395
DB	Abstract of EP 202,538
DC	Abstract of EP 16,371
DD	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
DE	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.
DF	Audia, James E., et al., "Potent, Selective Tetrahydro- $\beta$ -carboline Antagonists of the Serotonin 2B (5HT <sub>2B</sub> ) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
DG	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT <sub>2B</sub> Receptor Antagonist," March 17, 1995, pages 855-57.
DH	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. <sup>1</sup> A Generalised Monocyclic Rearrangement," 1967, 2005-07.
DI	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
DJ	G. Daum, et al., "The ins and outs of Raf Kinases," TIBS 19, November 1994, pages 474-80.
DK	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
DL	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NR1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
DM	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
DN	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
DO	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
DP	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
DQ	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
DR	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
DS	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
DT	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742.
Examiner	
Date Considered	